These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
2. Is the rapid virologic response a positive predictive factor of sustained virologic response in all pretreatment status genotype 1 hepatitis c patients treated with peginterferon-alpha2b and ribavirin? de Segadas-Soares JA; Villela-Nogueira CA; Perez RM; Nabuco LC; Brandão-Mello CE; Coelho HS J Clin Gastroenterol; 2009 Apr; 43(4):362-6. PubMed ID: 19077732 [TBL] [Abstract][Full Text] [Related]
3. Peginterferon alfa-2a plus ribavirin for the treatment of dual chronic infection with hepatitis B and C viruses. Liu CJ; Chuang WL; Lee CM; Yu ML; Lu SN; Wu SS; Liao LY; Chen CL; Kuo HT; Chao YC; Tung SY; Yang SS; Kao JH; Liu CH; Su WW; Lin CL; Jeng YM; Chen PJ; Chen DS Gastroenterology; 2009 Feb; 136(2):496-504.e3. PubMed ID: 19084016 [TBL] [Abstract][Full Text] [Related]
4. Peginterferon Alfa-2a plus ribavirin for chronic hepatitis C virus infection in HIV-infected patients. Torriani FJ; Rodriguez-Torres M; Rockstroh JK; Lissen E; Gonzalez-García J; Lazzarin A; Carosi G; Sasadeusz J; Katlama C; Montaner J; Sette H; Passe S; De Pamphilis J; Duff F; Schrenk UM; Dieterich DT; N Engl J Med; 2004 Jul; 351(5):438-50. PubMed ID: 15282351 [TBL] [Abstract][Full Text] [Related]
5. Predictive factors of early and sustained responses to peginterferon plus ribavirin combination therapy in Japanese patients infected with hepatitis C virus genotype 1b: amino acid substitutions in the core region and low-density lipoprotein cholesterol levels. Akuta N; Suzuki F; Kawamura Y; Yatsuji H; Sezaki H; Suzuki Y; Hosaka T; Kobayashi M; Kobayashi M; Arase Y; Ikeda K; Kumada H J Hepatol; 2007 Mar; 46(3):403-10. PubMed ID: 17126448 [TBL] [Abstract][Full Text] [Related]
6. Rapid virological response to peginterferon and ribavirin for hepatitis C genotype 1: the role of weight-based ribavirin exposure. Yu ML; Dai CY; Huang JF; Chuang WL Hepatology; 2008 Sep; 48(3):1019-20; author reply 1020-1. PubMed ID: 18756469 [No Abstract] [Full Text] [Related]
7. Prediction of sustained virological response by ribavirin plasma concentration at week 4 of therapy in hepatitis C virus genotype 1 patients. Maynard M; Pradat P; Gagnieu MC; Souvignet C; Trepo C Antivir Ther; 2008; 13(4):607-11. PubMed ID: 18672540 [TBL] [Abstract][Full Text] [Related]
8. Scientific rationale and study design of the individualized dosing efficacy vs flat dosing to assess optimal pegylated interferon therapy (IDEAL) trial: determining optimal dosing in patients with genotype 1 chronic hepatitis C. McHutchison J; Sulkowski M J Viral Hepat; 2008 Jul; 15(7):475-81. PubMed ID: 18363672 [TBL] [Abstract][Full Text] [Related]
9. Predicting treatment outcome following 24 weeks peginterferon alpha-2a/ribavirin therapy in patients infected with HCV genotype 1: utility of HCV-RNA at day 0, day 22, day 29, and week 6. Lukasiewicz E; Hellstrand K; Westin J; Ferrari C; Neumann AU; Pawlotsky JM; Schalm SW; Zeuzem S; Veldt BJ; Hansen BE; Verhey-Hart E; Lagging M Hepatology; 2007 Jan; 45(1):258-9. PubMed ID: 17187414 [No Abstract] [Full Text] [Related]
10. Peginterferon alpha-2a (40 KD) plus ribavirin for the treatment of chronic hepatitis C in Japanese patients. Kuboki M; Iino S; Okuno T; Omata M; Kiyosawa K; Kumada H; Hayashi N; Sakai T J Gastroenterol Hepatol; 2007 May; 22(5):645-52. PubMed ID: 17444850 [TBL] [Abstract][Full Text] [Related]
11. Consensus guidelines for the management of hepatitis C infection. Consensus Guidelines Committee for the Management of Hepatitis C Infection Saudi Med J; 2003 Jul; 24 Suppl 2():S99-118. PubMed ID: 25121186 [TBL] [Abstract][Full Text] [Related]
13. Treatment of acute HCV infection in HIV-positive patients: experience from a multicentre European cohort. Vogel M; Dominguez S; Bhagani S; Azwa A; Page E; Guiguet M; Valantin MA; Katlama C; Rockstroh JK; Nelson M Antivir Ther; 2010; 15(2):267-79. PubMed ID: 20386082 [TBL] [Abstract][Full Text] [Related]
14. Peginterferon alfa-2a plus ribavirin for chronic hepatitis C virus infection. Fried MW; Shiffman ML; Reddy KR; Smith C; Marinos G; Gonçales FL; Häussinger D; Diago M; Carosi G; Dhumeaux D; Craxi A; Lin A; Hoffman J; Yu J N Engl J Med; 2002 Sep; 347(13):975-82. PubMed ID: 12324553 [TBL] [Abstract][Full Text] [Related]
15. Improved outcomes in patients with hepatitis C with difficult-to-treat characteristics: randomized study of higher doses of peginterferon alpha-2a and ribavirin. Fried MW; Jensen DM; Rodriguez-Torres M; Nyberg LM; Di Bisceglie AM; Morgan TR; Pockros PJ; Lin A; Cupelli L; Duff F; Wang K; Nelson DR Hepatology; 2008 Oct; 48(4):1033-43. PubMed ID: 18697207 [TBL] [Abstract][Full Text] [Related]
16. Shortened treatment duration in treatment-naive genotype 1 HCV patients with rapid virological response: a meta-analysis. Moreno C; Deltenre P; Pawlotsky JM; Henrion J; Adler M; Mathurin P J Hepatol; 2010 Jan; 52(1):25-31. PubMed ID: 19931204 [TBL] [Abstract][Full Text] [Related]
17. Hepatitis C virus genotype 4 therapy: progress and challenges. Kamal SM Liver Int; 2011 Jan; 31 Suppl 1():45-52. PubMed ID: 21205137 [TBL] [Abstract][Full Text] [Related]
18. Peginterferon alfa-2a/ribavirin for 48 or 72 weeks in hepatitis C genotypes 1 and 4 patients with slow virologic response. Ferenci P; Laferl H; Scherzer TM; Maieron A; Hofer H; Stauber R; Gschwantler M; Brunner H; Wenisch C; Bischof M; Strasser M; Datz C; Vogel W; Löschenberger K; Steindl-Munda P; Gastroenterology; 2010 Feb; 138(2):503-12, 512.e1. PubMed ID: 19909752 [TBL] [Abstract][Full Text] [Related]
19. Impact of ribavirin dose reductions in hepatitis C virus genotype 1 patients completing peginterferon alfa-2a/ribavirin treatment. Reddy KR; Shiffman ML; Morgan TR; Zeuzem S; Hadziyannis S; Hamzeh FM; Wright TL; Fried M Clin Gastroenterol Hepatol; 2007 Jan; 5(1):124-9. PubMed ID: 17196435 [TBL] [Abstract][Full Text] [Related]
20. Influence of body mass index, cholesterol, triglycerides and steatosis on pegylated interferon alfa-2a and ribavirin treatment for recurrent hepatitis C in patients transplanted for HCV and alcoholic cirrhosis. Testino G; Sumberaz A; Ancarani AO; Borro P; Ravetti G; Ansaldi F; Andorno E; Gentile R; Icardi G Hepatogastroenterology; 2009; 56(90):501-3. PubMed ID: 19579629 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]